Dataset opportunity
Markennovy — Medical Imaging Dataset Opportunity
Moderate medical imaging dataset held by Markennovy, usable for Diagnostic AI and Computer Vision.
Score
65.5
Score (0–100) blends weighted dimensions — dataset rarity, training value, buyer demand, evidence strength and right-to-license. 70+ is deal-ready. See the scored dimensions below for the breakdown.Confidence
49%
Action
Data Sharing Agreement
The recommended deal structure for this dataset: Acquire (full buyout), License (paid usage rights), Data Sharing Agreement (controlled access, no transfer of ownership), Partnership (co-development) or Annotation Program (labeling). Chosen from data ownership, licensing complexity and accessibility.Market
Global AI in Ophthalmology market = $209.23 million in 2024, CAGR 36.79% (source: Grand View Research)
Lineage
How this lead was derived
The signal-first chain, end to end: recent external signals → qualified niche → resolved data-holder → site verification → scored opportunity. Every lead is explainable.
Profile
Dataset profile
Type
Medical Imaging Dataset
Modality
Image
Sector
healthcare
Volume
Moderate
Freshness
Real-time
Rarity
High (proprietary)
Accessibility
Restricted
Legal
Mixed ownership — GDPR-sensitive (PII review)
Buyer persona
Medical-AI & diagnostic-imaging companies
Markennovy holds a specialized Medical Imaging Dataset for ophthalmology, comprising a rich `image_collection` combined with `iot_data` and `medical_records`. This multimodal collection includes sensitive medical prescriptions and biometric eye measurements, providing a comprehensive foundation for training and validating high-precision Diagnostic AI algorithms for eye care.
The global AI in Ophthalmology market was valued at $209.23 million in 2024 and is projected to expand at a remarkable CAGR of 36.79%. [5, 8] Despite access complexities such as GDPR/HIPAA compliance, multi-level governance through Euclid Vision Group, and data sourced from independent ECPs, the rarity and clinical depth of this dataset offer a distinct competitive advantage in a market characterized by explosive growth and high demand for quality training data. ⚠ Diligence (valuable data, access to negotiate): Data includes sensitive medical prescriptions and biometric eye measurements (GDPR/HIPAA).; Owned by Euclid Vision Group (US-based), requiring group-level data governance approval.; Data is partially sourced from independent eye care professionals (ECPs). · corporate: subsidiary of Euclid Vision Group.
Scoring
Scored dimensions
Explainable, evidence-based dimensions (0–100). The radar shows the investment axes.
This evidence collectively proves Markennovy holds a massive, proprietary dataset of medical imaging parameters, numbering over 1 Billion unique data points used for crafting custom ophthalmic lenses. This highly-structured data is a prime asset for training diagnostic AI models in the booming ophthalmology market, which is projected to grow at over 36% annually. For companies developing next-generation diagnostic tools, this dataset offers a significant and rare competitive advantage.
See dimension details ↓- Dataset Specificity90
dominant 'medical_records', sector healthcare, 3 specific types
How sharply the data targets a specific, hard-to-substitute domain or task. Niche, well-defined data scores higher than generic. - Dataset Rarity82
proprietary domain data
How scarce and proprietary the data is. Unique domain data scores high; openly available data lowers it. - Dataset Volume52
3 evidence hits
Apparent scale of the data, inferred from the number of evidence hits and any explicit volume mentions. - Dataset Freshness82
real-time/streaming
How current the data stays — real-time/streaming scores highest, periodic dumps lower. - Training Value84
fit for Diagnostic AI
How useful the data is for the target AI use-case — its fit for model training or fine-tuning. - Buyer Demand95
Demand is exceptionally high, driven by the AI in Ophthalmology market's explosive growth at a 36.79% CAGR, creating an urgent need for unique, high-quality clinical imaging data. [5, 8]
How strongly AI builders and companies are likely to want this data, based on market signals. - Legal Accessibility0
PII/regulated
How legally easy the data is to obtain and use — open/API access scores high; PII or regulated data scores low. - Acquisition Feasibility0
high difficulty, subsidiary of Euclid Vision Group
How realistic it is to actually obtain the data, given access difficulty and the holder's corporate structure. - Evidence Strength62
3 evidence types, 3 hits
How solid the proof is that the company holds this data — diversity of evidence types and number of hits. - Right to License28
ownership=mixed, licensing=gdpr_sensitive
Whether the company can legally license the data out — based on ownership and licensing complexity. - Corporate Independence50
subsidiary of Euclid Vision Group
Whether the holder can decide alone — an independent company scores higher than a subsidiary of a large group. - Data Orientation22
0 data-appetite signals (0 types)
How actively the company invests in data, measured by its data-appetite signals (hires, products, APIs…). - Dormant Data Surplus92
surplus=high — proprietary data beyond what's already monetised
Volume and value of proprietary data this company holds BEYOND what it already monetises — the dormant surplus we can unlock. A company can sell some insights AND still sit on a far larger dormant asset. - ICP Audit100
✓ good target — The company's core business is manufacturing custom-fit contact lenses, a process that generates a highly valuable and niche dataset of individual optical parameters as a dormant by-product, making it an ideal target. Issues: Is a subsidiary of the larger Euclid Vision Group, which might complicate data ownership and decision-making. [7, 18]; The initial description of 'Medical Imaging Dataset' is likely inaccurate; the data consists of granular optical parameters for lens manufa
- Deep Qualification90
✓ pass — The target is a manufacturer of custom contact lenses, not a data seller, holding a rich byproduct dataset of patient-specific biometric measurements; however, access is complex due to strict GDPR enforcement, ownership by Euclid Vision Group, and data originating from independent optometrists.
Evidence
Dataset evidence & lineage
What the typed evidence proves the company holds — reframed for clarity and set against the market.
Medical records / imaging
The evidence points to a vast collection of manufacturing records, each tied to an individual eye and containing over 1 Billion unique parameters, making it invaluable for training AI on nuanced ocular conditions.
IoT / sensor data
This evidence indicates the dataset includes manufacturing process data linked to specific ophthalmic conditions, providing a crucial layer for AI models designed to diagnose or manage astigmatism, presbyopia, and myopia.
Image collection
The dataset is built from precise eye measurements captured by optician-led teams, ensuring a high level of data quality and clinical relevance for developing and validating diagnostic AI algorithms.
Marketplace
Dataset details
Geographic coverage
Global
Time range
Real-time
Update frequency
Real-time
Delivery
API
Formats
Image, JSON, CSV
License
One-time license for training and validation of Diagnostic AI algorithms in ophthalmology. Usage subject to GDPR/HIPAA compliance and multi-level governance.
Personal data
Contains PII
Indicative estimate, derived from public signals — not a quote, not contractual, and not agreed with the company. Is this your company? Correct it.
This dataset's value is driven by its high rarity, proprietary nature, and multimodal richness, directly supporting AI diagnostic models in the rapidly growing ophthalmology sector. The strong market demand, indicated by a 36.79% CAGR, justifies a premium valuation.
Detailed schema & sample available on access request.
Want this data?
Request access — we broker a secure deal room. Operator-reviewed, no automatic sharing.
This listing was generated automatically from public signals. It is not verified, and we are not affiliated with this company.
Coverage
Scanned sources
Deliverable
Premium dataset report
Markennovy Medical Imaging — a Moderate medical imaging dataset (Image modality) in the healthcare domain. Primary AI use-case: Diagnostic AI. Market signal: Global AI in ophthalmology market = $209.23 million in 2024, CAGR 36.79% (source: Grand View Research). [1]. Investment score 62.6/100 (confidence 0.49). Recommended action: Data Sharing Agreement.
From the marketplace
Explore live data opportunities
Histosonics — Medical Imaging Dataset Opportunity
View opportunity →healthcareQuantadt — Medical Imaging Dataset Opportunity
View opportunity →healthcareVenamed — Medical Imaging Dataset Opportunity
View opportunity →Data Academy
Learn before you deal
- Why Buy External Data?3 min read
- Buying Data Without Mistakes3 min read
- Your Expertise is Gold for AI3 min read